Second-line chemotherapy for patients with advanced gastric cancer.

about

Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer

P2860

Q52682256-9FAA0073-018B-4A93-B46C-8D46E8DEC6DD Q57074267-EFB3AEB9-19A2-4402-897D-42336FCB0DFE

P2860

Second-line chemotherapy for patients with advanced gastric cancer.

Item

http://www.wikidata.org/entity/Q38750633

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Second-line chemotherapy for patients with advanced gastric cancer.

@en

type

Item

label

Second-line chemotherapy for patients with advanced gastric cancer.

@en

prefLabel

Second-line chemotherapy for patients with advanced gastric cancer.

@en

P1476

Second-line chemotherapy for patients with advanced gastric cancer

@en

P2093

Daisuke Takahari

http://www.w3.org/2001/XMLSchema#string

P2860

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Global cancer statistics, 2012

Stat3 as an oncogene

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

P2888

s10120-017-0707-8

P304

395-406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-017-0707-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daisuke Takahari

P577

2017-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084023958

http://www.w3.org/2001/XMLSchema#string

P698

28260227

http://www.w3.org/2001/XMLSchema#string

Second-line chemotherapy for patients with advanced gastric cancer.

about

P2860

P2860

Second-line chemotherapy for patients with advanced gastric cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698